In a univariate analysis, CYP2W1 immunoreactivity was not associated with prognosis for both OS (n = 196 patients from first surgery, median 71.5 vs 43 months with high and low CYP levels, respectively, HR = 1.22, 95% CI = 0.8–1.8, P = 0.33) and DFS (n = 50 patients with complete tumor resection after first surgery, median 38 vs 27 months, HR = 1.42, 95% CI = 0.6–3.2, P = 0.47). This evidence concerns the gene CYP2W1 and neoplasm.